The effects of doxorubicin on blood-brain barrier integrity in hCMEC/D3.

ABSTRACT: Current chemotherapy regimens have significantly improved overall survival for children with cancer. However, these treatments are associated with detrimental side effects like chemotherapy-induced cognitive impairment (CICI), or "chemobrain." Measurable deficits in cognitive function persist years after treatment. Specifically, doxorubicin (DOXO), a commonly used chemotherapeutic agent in curative regimens for children with cancer, plays a pivotal role in the development of CICI, even though it doesn't cross the blood-brain barrier (BBB). Using a juvenile rat model, we found that DOXO compromises the BBB integrity. To further address the poorly understood mechanism of DOXO-related CICI, we utilized human cerebral microvascular endothelial cells (hCMEC/D3) to study the changes induced by D

SUBMITTER: Patel C 

PROVIDER: S-EPMC12828330 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature